Replacing two cycles of intensive chemotherapy with Blincyto raised four-year event-free survival to 83% from 70.3% in children with high-risk B-cell ALL, with far fewer infections.
|Articles|August 11, 2011
Advanced screening of 50/50 in California
Author(s)Lindsay Ray
Advertisement
One of our readers sent us an email letting us know about an advanced screening of 50/50, the upcoming Joseph Gordon-Levitt and Seth Rogen movie about a young man's cancer journey, in San Marcos, California. The screening will be held on Tuesday, Aug. 16 at 7 p.m. Go to
Advertisement
Related to this article
In a trial of 2,175 people with early HER2-positive breast cancer, 43.8% had no invasive cancer left after 12 weeks of a lighter regimen, and certain tumor features predicted who was most likely to respond.
Median progression-free survival reached 24.9 months with Tukysa plus Herceptin and Perjeta versus 16.3 months with placebo plus Herceptin and Perjeta.
A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused fewer serious side effects than chemotherapy.
In a study of more than 250,000 older adults presented at ASTRO 2026, people with depression who started talk therapy within a week of their cancer diagnosis had a 27% lower risk of dying from their cancer. But most people with depression received no mental health treatment at all.
Epkinly plus R-CHOP lowered the risk of disease progression or death by 51% versus R-CHOP alone in patients with newly diagnosed diffuse large B-cell lymphoma.
Living with incurable small lymphocytic lymphoma means facing new health challenges and fears while finding a balance between caution, optimism and daily life.
Breast cancer survivor Sue Weldon discusses survivorship gaps, integrative therapies alongside treatment and why caregivers should prioritize themselves.
Advertisement
Advertisement
Trending on CURE
1
Exercise Gave Me Control. It Didn’t Cure My Cancer
2
Living With Incurable Cancer: The Emotional Toll of Never Knowing What Comes Next
3
FDA Approves Tukysa Combination as Maintenance for HER2-Positive Breast Cancer
4
Epkinly Plus R-CHOP Cuts Lymphoma Progression Risk by 51% in Phase 3 Trial
5